PTN抗体

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human colon cancer tissue, Primary antibody: P04432(PTN Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

Pleiotrophin (PTN), also known as heparin-binding growth-associated molecule (HB-GAM), is a secreted cytokine belonging to the neurite growth-promoting factor family. First identified in the 1980s, PTN plays critical roles in embryonic development, tissue repair, and pathological processes such as tumorigenesis. It binds to cell surface receptors like receptor protein tyrosine phosphatase beta/zeta (RPTPβ/ζ) and integrins, activating downstream signaling pathways (e.g., PI3K/AKT, MAPK) that regulate cell proliferation, migration, angiogenesis, and stem cell differentiation.

PTN overexpression is linked to various cancers, including glioblastoma, melanoma, and breast cancer, where it promotes tumor growth, metastasis, and resistance to therapy. It also contributes to neurodegenerative diseases and inflammatory conditions. PTN antibodies, either monoclonal or polyclonal, are essential research tools for detecting PTN expression in tissues or serum, elucidating its biological functions, and validating its role in disease mechanisms.

Therapeutic PTN-targeting antibodies are under investigation to block PTN-receptor interactions, aiming to inhibit tumor progression or modulate tissue regeneration. Challenges include optimizing antibody specificity and delivery, as PTN’s pleiotropic effects involve complex interactions within the extracellular matrix. Recent studies also explore PTN as a biomarker for cancer prognosis. Overall, PTN antibodies hold promise for both basic research and translational applications in oncology and regenerative medicine.